Influence of methylprednisolone on the reversal time of sugammadex: a randomized clinical trial

Kocaoglu M. H., MEÇO B. C., ÖZÇELİK M., BATİSLAM Y.

REVISTA BRASILEIRA DE ANESTESIOLOGIA, vol.70, no.2, pp.111-117, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 70 Issue: 2
  • Publication Date: 2020
  • Doi Number: 10.1016/j.bjan.2020.01.002
  • Journal Name: REVISTA BRASILEIRA DE ANESTESIOLOGIA
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
  • Page Numbers: pp.111-117
  • Keywords: Sugammadex, Rocuronium, TOF, Methytprednisolone, Recovery, RESIDUAL NEUROMUSCULAR BLOCKADE, POSTEXTUBATION LARYNGEAL EDEMA, BLOCKING-AGENTS, DEXAMETHASONE, PREVENTION, MANAGEMENT
  • Ankara University Affiliated: Yes

Abstract

Background and objectives: Sugammadex is a modified gamma-cyclodextrin that reverses the effects of aminosteroidal neuromuscular blocking agents. Likewise, some steroid molecules, such as toremifene, fusidic acid, and flucloxacillin, can also be encapsulated by sugammadex. Methylprednisolone, which is a synthetic steroid used commonly for airway oedema prophylaxis, can also be encapsulated by sugammadex. The objective of this study was to compare the recovery times of sugammadex for reversing rocuronium-induced moderate neuromuscular blockade in those who received intraoperative 1 nng.kg(-1) methylprednisolone or saline.